Cargando…
Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients
Molecular portraits of numerous tumors have flooded oncologists with vast amounts of data. In parallel, effective inhibitors of central pathways have shown great clinical benefit. Together, this promises potential clinical benefits to otherwise end-stage cancer patients. Here, we report a clinical s...
Autores principales: | Zick, Aviad, Peretz, Tamar, Lotem, Michal, Hubert, Ayala, Katz, Daniela, Temper, Mark, Rottenberg, Yakir, Uziely, Beatrice, Nechushtan, Hovav, Meirovitz, Amichai, Sonnenblick, Amir, Sapir, Eli, Edelman, David, Goldberg, Yael, Lossos, Alexander, Rosenberg, Shai, Fried, Iris, Finklstein, Ruth, Pikarsky, Eli, Goldshmidt, Hanoch |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440149/ https://www.ncbi.nlm.nih.gov/pubmed/28514312 http://dx.doi.org/10.1097/MD.0000000000006931 |
Ejemplares similares
-
Clinical Characteristics, Response to Platinum-Based Chemotherapy and Poly (Adenosine Phosphate-Ribose) Polymerase Inhibitors in Advanced Lung Cancer Patients Harboring BRCA Mutations
por: Arnon, Johnathan, et al.
Publicado: (2023) -
Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes
por: Maoz, Myriam, et al.
Publicado: (2019) -
Author Correction: Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes
por: Maoz, Myriam, et al.
Publicado: (2020) -
Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations
por: Nechushtan, Hovav, et al.
Publicado: (2009) -
Temporal trends of geographic variation in mortality following cancer diagnosis: a population-based study
por: Rottenberg, Yakir, et al.
Publicado: (2019)